September 19, 2006 – ImClone lost a patent suit on Erbitux, the monoclonal antibody that provides all of its revenues; Schering and Organon ended a partnership that was developing a male contraceptive; Nymox Pharma released positive data on its drug for benign prostatic hyperplasia; Sanofi-pasteur began a Phase I trial of its H7N1 pandemic vaccine; Cell Therapeutics floated a 23 million share issue to raise $40 million; and Novavax began preclinical tests of a nasally-delivered flu vaccine. The Centient Biotech 200™ lost 16 points to close at 3719.23, a decrease of .43%. More details...
